Tirschwell & Loewy Inc. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 94.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,530 shares of the life sciences company’s stock after acquiring an additional 11,445 shares during the period. Illumina comprises about 1.0% of Tirschwell & Loewy Inc.’s investment portfolio, making the stock its 29th biggest position. Tirschwell & Loewy Inc.’s holdings in Illumina were worth $7,311,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of ILMN. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after buying an additional 39 shares in the last quarter. Proficio Capital Partners LLC boosted its position in Illumina by 61.7% in the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Lake Point Wealth Management acquired a new position in Illumina in the fourth quarter valued at about $30,000. Moody National Bank Trust Division acquired a new position in Illumina in the fourth quarter valued at about $31,000. Finally, Virtus ETF Advisers LLC acquired a new position in Illumina in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 90.51% of the company’s stock.
In related news, Director Robert S. Epstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $280.11, for a total transaction of $280,110.00. Following the completion of the sale, the director now directly owns 4,256 shares of the company’s stock, valued at $1,192,148.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $293.66, for a total transaction of $969,078.00. Following the sale, the director now directly owns 358,929 shares of the company’s stock, valued at $105,403,090.14. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,526 shares of company stock valued at $9,602,911. 0.38% of the stock is currently owned by insiders.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.26. The business had revenue of $846.00 million during the quarter, compared to the consensus estimate of $838.70 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. Illumina’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.45 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post 6.53 earnings per share for the current fiscal year.
ILMN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 price target on the stock in a research report on Friday, January 11th. Bank of America restated a “buy” rating and issued a $355.00 price target on shares of Illumina in a research report on Wednesday, January 30th. Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a research report on Friday, January 25th. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Finally, Morgan Stanley reduced their target price on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a research report on Monday, January 7th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Illumina presently has an average rating of “Buy” and a consensus target price of $352.81.
TRADEMARK VIOLATION NOTICE: This article was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/illumina-inc-ilmn-shares-bought-by-tirschwell-loewy-inc.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: Understanding Average Daily Trade Volume
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.